Lantus, Insulin Glargine News

We examined the risk of development of solid tumours in relation to treatment with oral agents, human insulin and insulin analogues.

To ensure that the safety profile of the human hormone is not compromised by the molecular modifications, the toxico-pharmacological properties of insulin analogs should be carefully monitored.

In order to achieve tight glycaemic control and improve the quality of life for diabetic patients, a number of novel insulin preparations, insulin analogues, have been constructed thanks to recombinant DNA technologies and advanced protein chemistry.

Are there any "New" treatments or even a "Cure" for Diabetes Type 2? 12/19/09 Alan "SadSack" Beeching Topics: Ask the Expert G'day to all, I'm a "newbie" in this Forum.

Since having diabetes can be a big pain in the neck anytime, but particularly around the holidays, I thought it might be humorous to go on the offensive and add a "D" twist to an age old Christmas carol.

Abstract Objective: To determine whether metformin-treated patients with type 2 diabetes given an analogue mixture of basal and rapid-acting insulins would have less glycemic variability than patients given basal insulin glargine.Methods: Two post hoc analyses were used to compare 7-point blood glucose profiles from 3 published studies comparing ...

PARIS An investigational diabetes drug developed by Roche and Ipsen offers glycemic control comparable to that of an insulin produced by Sanofi-Aventis, according to results of two late-stage clinical trials announced Thursday.

Dec 17, 2009 - Regulatory News: Ipsen , an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed headline results of the fourth and fifth of eight T-emerge phase III studies in patients with diabetes for taspoglutide, the first once weekly glucagon-like peptide-1 analogue based on a human ...

RESEARCH DESIGN AND METHODS: This 28-week parallel-group study randomized 233 insulin-naive patients with HbA values>/=8.0% on>1,000 mg/day metformin alone or in combination with other OADs.

A recent study, published in the December issue of Mayo Clinic Proceedings , demonstrates new survival data for the blood disorder myelofibrosis.

Type 2 diabetes and obesity are linked to an increased risk of certain cancers. Recently published studies suggested that insulin glargine , may be associated with a higher risk of certain cancers than other insulins or oral glucose lowering medications.

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the type 2 diabetes drug market in Brazil will grow from $417 million in 2008 to $834 million in 2013.

Shedding Light on the Co-morbidities of Diabetes The Complications of Having Rheumatoid Arthritis and Diabetes Insulin shots vs insulin pump 11/18/09 yoli Topics: Insulin shots vs insulin pump I have been a diabetic for 10 years.

The social policy ministry is expected to rectify a long-standing, and painful issue for sufferers of diabetes.

Privately held Wellstat Therapeutics Corp. stands to gain up to $350 million, including an undisclosed up-front payment, in exchange for global rights to its Type II diabetes oral insulin sensitizer PN2034 and related compounds in a development and commercialization deal with Sanofi-Aventis Group SA, which sought the licensing agreement to beef up ...

Paris, October 21, 2009 Sanofi-aventis and Wellstat Therapeutics Corporation announced today a global licensing agreement on PN2034, a novel oral first-in-class, insulin sensitizer, for the treatment of Type II Diabetes.

A meta-analysis of clinical data published today in Diabetologia, the medical journal for the European Association for the Study of Diabetes , demonstrated that the Novo Nordisk long-acting insulin Levemir was not associated with any increase in the incidence of cancer when compared to human insulin .

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that biosimilar insulins and insulin analogues stand to erode $6.1B in brand sales in the U.S. and Europe by 2018, saving healthcare systems $3.8B in the process.

Provincial drug plans often follow the coverage recommendations of Canada's Common Drug Review board.

Findings demonstrate that Type 2 diabetes patients starting insulin treatment with once-daily injection of NovoMix 30 achieve a significantly greater HbA reduction compared to patients starting with a daily injection of insulin glargine.